In vitro evaluation of guanidine analogs as sigma receptor ligands for potential anti-stroke therapeutics

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 155-166

  Behensky, Adam A ^a   Cortes Salva, Michelle ^b   Seminerio, Michael J ^c   Matsumoto, Rae R ^c   Antilla, Jon C ^b   Cuevas, Javier ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (3,4 DICHLOROPHENYL)ETHYL] 4 METHYLPIPERAZINE; BD 1063; GUANIDINE DERIVATIVE; N,N' DI 2 TOLYL GUANIDINE; N,N' DI 3 TOLYL GUANIDINE; N,N' DI 4 BROMOPHENYL GUANIDINE; N,N' DI 4 TOLYL GUANIDINE; N,N' DIPHENYL GUANIDINE; OPIATE ANTAGONIST; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EMBRYO; FLUOROMETRY; HOMOGENATE; IC 50; IN VITRO STUDY; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ACIDOSIS; ANIMALS; BINDING, COMPETITIVE; BRAIN ISCHEMIA; CALCIUM; CELL MOVEMENT; GUANIDINE; LIGANDS; MICROGLIA; MOLECULAR CONFORMATION; PARASYMPATHOMIMETICS; RATS; RECEPTORS, SIGMA; STROKE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871705390     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199513     Document Type: Article

References (39)

1. Ajmo CT, Jr, Vernon DO, Collier L, Pennypacker KR, and Cuevas J (2006) Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Curr Neurovasc Res 3:89-98. (Pubitemid 43778702)
2. Cobos EJ, Entrena JM, Nieto FR, Cendán CM, and Del Pozo E (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6: 344-366.
3. Cortes-Salva M, Nguyen BL, Cuevas J, Pennypacker KR, and Antilla JC (2010) Copper-catalyzed guanidinylation of aryl iodides: the formation of N,N' -disubstituted guanidines. Org Lett 12:1316-1319.
4. Cuevas J, Behensky A, Deng W, and Katnik C (2011a) Afobazole modulates neuronal response to ischemia and acidosis via activation of sigma-1 receptors. J Pharmacol Exp Ther 339:152-160.
5. Cuevas J and Berg DK (1998) Mammalian nicotinic receptors with alpha7 subunits that slowly desensitize and rapidly recover from alpha-bungarotoxin blockade. J Neurosci 18:10335-10344. (Pubitemid 29016553)
6. Cuevas J, Rodriguez A, Behensky A, and Katnik C (2011b) Afobazole modulates microglial function via activation of both sigma-1 and sigma-2 receptors. J Pharmacol Exp Ther 339:161-172.
7. de Candia M, Liantonio F, Carotti A, De Cristofaro R, and Altomare C (2009) Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation. J Med Chem 52: 1018-1028.
8. Derex L and Nighoghossian N (2008) Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry 79: 1093-1099.
9. Dussossoy D, Carayon P, and Belugou S, et al. (1999) Colocalization of sterol isomerase and sigma(1) receptor at endoplasmic reticulum and nuclear envelope level. Eur J Biochem 263:377-386.
10. Faustino JV, Wang X, Johnson CE, Klibanov A, Derugin N, Wendland MF, and Vexler ZS (2011) Microglial cells contribute to endogenous brain defenses after acute neonatal focal stroke. J Neurosci 31:12992-13001.
11. Gentry CL, Egleton RD, Gillespie T, Abbruscato TJ, Bechowski HB, Hruby VJ, and Davis TP (1999) The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides 20:1229-1238. (Pubitemid 29512444)
12. Gerebtzoff G, Li-Blatter X, Fischer H, Frentzel A, and Seelig A (2004) Halogenation of drugs enhances membrane binding and permeation. ChemBioChem 5 :676-684. (Pubitemid 39257090)
13. Glennon RA (2005) Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the "deconstruction-reconstruction- elaboration" approach. Mini Rev Med Chem 5:927-940.
14. Hall AA, Herrera Y, Ajmo CT, Jr, Cuevas J, and Pennypacker KR (2009) Sigma receptors suppress multiple aspects of microglial activation. Glia 57:744-754.
15. Herrera Y, Katnik C, Rodriguez JD, Hall AA, Willing A, Pennypacker KR, and Cuevas J (2008) sigma-1 receptor modulation of acid-sensing ion channel a (ASIC1a) and ASIC1a-induced Ca2+ influx in rat cortical neurons. J Pharmacol Exp Ther 327:491-502.
16. Jiang G, Mysona B, Dun Y, Gnana-Prakasam JP, Pabla N, Li W, Dong Z, Ganapathy V, and Smith SB (2006) Expression, subcellular localization, and regulation of sigma receptor in retinal muller cells. Invest Ophthalmol Vis Sci 47:5576-5582. (Pubitemid 46723812)
17. Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, and Cuevas J (2006) Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther 319:1355-1365.
18. Lee G, Dallas S, Hong M, and Bendayan R (2001) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596. (Pubitemid 33136238)
19. Lloyd-Jones D, Adams R, and Carnethon M, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: e21-e181.
20. Löscher W, Wlaź P, and Szabo L (1998) Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats. Neurosci Lett 240: 33-36. (Pubitemid 28137289)
21. Madden KP, Clark WM, and Zivin JA (1993) Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke 24: 1068-1071. (Pubitemid 23201468)
22. Mari Y, Katnik C, and Cuevas J (2010) ASIC1a channels are activated by endogenous protons during ischemia and contribute to synergistic potentiation of intracellular Ca(2+) overload during ischemia and acidosis. Cell Calcium 48:70-82.
23. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, and De Costa BR (1995) Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280:301-310.
24. Meunier J and Hayashi T (2010) Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther 332:388-397.
25. Muir KW (2006) Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 6:53-60.
26. Muñoz Maniega S, Cvoro V, Chappell FM, Armitage PA, Marshall I, Bastin ME, and Wardlaw JM (2008) Changes in NAA and lactate following ischemic stroke: a serial MR spectroscopic imaging study. Neurology 71:1993-1999.
27. Nakazawa M, Matsuno K, and Mita S (1998) Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures. Neurochem Int 32: 337-343. (Pubitemid 28174985)
28. Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, and Ruoho AE (2007) Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol 72:921-933. (Pubitemid 47481415)
29. Reddy NL, Hu LY, and Cotter RE, et al. (1994) Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'- methylguanidine: a new, selective noncompetitive NMDA receptor antagonist. J Med Chem 37:260-267. (Pubitemid 24063045)
30. Scherz MW, Fialeix M, Fischer JB, Reddy NL, Server AC, Sonders MS, Tester BC, Weber E, Wong ST, and Keana JF (1990) Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor. J Med Chem 33:2421-2429. (Pubitemid 20274196)
31. Schetz JA, Perez E, Liu R, Chen S, Lee I, and Simpkins JW (2007) A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain Res 1181:1-9. (Pubitemid 350050910)
32. Shahaduzzaman M, McAleer J, Grieco J, Golden J, Glover J, Hall J, Cortes-Salva M, Antilla J, and Cuevas J, R. PK and Willing AE (2012) Sigma Receptor (sRs) Agonist NAPH Decreased Long-term Infarct Volume and Rescued White Matter After Middle Cerebral Artery Occlusion (MCAO). Cell Transplant 21:790.
33. Torrence-Campbell C and Bowen WD (1996) Differential solubilization of rat liver sigma 1 and sigma 2 receptors: retention of sigma 2 sites in particulate fractions. Eur J Pharmacol 304:201-210. (Pubitemid 26342691)
34. Vilner BJ and Bowen WD (2000) Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 292:900-911. (Pubitemid 30136581)
35. Weintraub MI (2006) Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke 37 :1917-1922.
36. Xiong ZG, Zhu XM, and Chu XP, et al. (2004) Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell 118:687-698.
37. Zhang H, Katnik C, and Cuevas J (2009) Sigma receptor activation inhibits voltagegated sodium channels in rat intracardiac ganglion neurons. Int J Physiol Pathophysiol Pharmacol 2:1-11.
38. Zhang H and Cuevas J (2002) Sigma receptors inhibit high-voltage- activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol 87: 2867-2879. (Pubitemid 34670667)
39. Zhang H and Cuevas J (2005) sigma Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 313:1387-1396. (Pubitemid 40727046)